Follow us on Twitter
twitter icon@FreshPatents

Autoimmune patents


This page is updated frequently with new Autoimmune-related patent applications.

SALE: 440+ Autoimmune-related patent PDFs

 Fluorometric immunoassay for detection of anti-dsdna antibodies patent thumbnailnew patent Fluorometric immunoassay for detection of anti-dsdna antibodies
The present invention relates to the field of immunological methods, more precisely to the field of detection methods for antibodies against double-stranded dna (dsdna) for diagnostics of chronic autoimmune diseases, such as systemic lupus erythematosus (sle). The fluorometric immunoassay method for detection of anti-dsdna solves the technical problem of designing a method for detection of the aforesaid antibodies, which would be faster, cheaper and less toxic as the standard farr-ria method, but would have the same diagnostic specificity (which is 100%) and improved diagnostic sensitivity (for 3%).
Univerzitetni Klinicni Center Ljubljana

 Activation and expansion of t-cells using an engineered multivalent signaling platform as a research tool patent thumbnailnew patent Activation and expansion of t-cells using an engineered multivalent signaling platform as a research tool
Provided are a system and methods for selectively inducing expansion of a population of t cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of ctls, preferably human ctls.
The Trustees Of The University Of Pennsylvania

 Tlr3 binding agents patent thumbnailnew patent Tlr3 binding agents
The present invention relates to antibodies (e.g. Monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind tlr3, and that optionally further modulate, e.g.
Innate Pharma

 Compositions and methods of use for therapeutic antibodies patent thumbnailnew patent Compositions and methods of use for therapeutic antibodies
The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
Novartis Ag

 Anti-ox40 antibodies and methods of use thereof patent thumbnailnew patent Anti-ox40 antibodies and methods of use thereof
The present disclosure provides antibodies that specifically bind to human ox40 receptor (ox40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human ox40 and modulate ox40 activity, e.g., enhance, activate, or induce ox40 activity, or reduce, deactivate, or inhibit ox40 activity.
Memorial Sloan-kettering Cancer Center

 Effector-deficient anti-cd32a antibodies patent thumbnailnew patent Effector-deficient anti-cd32a antibodies
Effector-deficient anti-cd32a monoclonal antibodies are encompassed, as are method and uses for treating cd32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.. .
Adventist Health System/sunbelt Inc.

 Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein patent thumbnailnew patent Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein
A tgal-3bp-fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing, reducing, suppressing or limiting metastasis of cancer cells, and immunosuppressing or modulating phagocytosis and t-cell functions by using the same are disclosed herein. The tgal-3bp-fc fusion protein comprises: a truncated gal-3 binding protein with domain 4, and at least an fc fragment of an immunoglobulin g.
Show-chwan Memorial Hospital

 Processes and intermediates for making a jak inhibitor patent thumbnailnew patent Processes and intermediates for making a jak inhibitor
This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of janus kinases (jak) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Incyte Holdings Corporation

 Granulysin in immunotherapy patent thumbnailnew patent Granulysin in immunotherapy
Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kd granulysin thereby producing a monocyte-derived dendritic cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

 Cytokine receptor peptides, compositions thereof and methods thereof patent thumbnailnew patent Cytokine receptor peptides, compositions thereof and methods thereof
The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a g-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
Symthera Canada Ltd.

new patent

Somatic stem cells

Described herein is a method of treating a disorder, the method comprising: administering to a subject in need thereof a composition that contains a population of somatic stem cells that are 0.3-6.0 micrometers in size and cd9+, cd349+, cd133−, cd90−, cd34−, ssea1+, ssea4+, cd13+, or stro1+, wherein the disorder is selected from the group consisting of a neurodegenerative disease, nervous system disorder, cancer, metabolic disorder, autoimmune disorder, inflammatory disorder, heart or circulatory disorder, blood disorder, muscular dystrophy, gastrointestinal disease, kidney disease, liver disease, lung disease, adrenal disorder, a condition resulting from an injury, a condition associated with aging, and virus infection.. .
Stembios Technologies, Inc.

new patent

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.

new patent

Non-human animals having a disruption in a c9orf72 locus

A non-human animal model for neurodegenerative and/or inflammatory diseases is provided, which non-human animal comprises a disruption in a c9orf72 locus. In particular, non-human animals described herein comprise a deletion of an entire coding sequence of a c9orf72 locus.
Regeneron Pharmaceuticals, Inc.

Cd37-binding molecules and immunoconjugates thereof

Methods of using cd37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to cd37 to deplete b-cells (e.g., non-cancerous b-cells) and methods of treating autoimmune and inflammatory diseases are further provided.. .
Immunogen, Inc.

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv

S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by pde7

The present invention relates to a family of s-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (pde7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.. .
Consejo Superior De Lnvestigaciones Cientificas (csic)

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

And their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.. .

Compositions and methods for treating autoimmune and inflammatory diseases

Compositions and methods are provided for the treatment and/or prevention of an inflammatory and/or autoimmune disease or disorder.. .
Trustees Of The Uniersity Of Pennsylvania

Use of cladribine for treating autoimmune inflammatory disease

2-chloro-2′-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as nmo e.g. In patients known to have nmo-igg seropositivity or in patients optic neuritis, myelitis and at least two of mri evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain mri nondiagnostic for multiple sclerosis or nmo-igg seropositivity..
Chord Therapeutics S.a.r.i.

Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus

Particle formulations are disclosed that include polymeric particles containing a small molecule drug and a high molecular weight therapeutic protein. Methods of making and using the particle formulations also are disclosed.
Duquesne University

Antigen-specific immunotherapy using tolerizing liposomes

The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic dendritic cells (dcs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of dcs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomes tailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory t cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokines at the site of antigen or allergen presentation.. .
Pls-design Gmbh

Liposome-based immunotherapy

The present invention provides a liposome encapsulating an autoantigen, wherein the liposome has a size comprised from 500 to 15000 nm and the liposome membrane comprises phosphatydilserine (ps) in an amount comprised from 10 to 40% by weight with respect to the total membrane liposomal composition. Pharmaceutical or veterinary compositions comprising a therapeutically effective amount of said liposome are also provided.
InstituciÓ Catalana De Recerca I Estudis AvanÇats

Method for identifying disease-associated cdr3 patterns in an immune repertoire

The present disclosure generally pertains to a method for developing diagnostic tests that are based on the immune response and the resulting immune repertoire. The presently disclosed method increases the signal and reduces the background to allow the identification of shared cdr3s that can be used to produce a disease signature.
Cb Biotechnologies, Inc.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Baff selective binding compounds and related methods

The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Ossianix, Inc.

Antigenic gm-csf peptides and antibodies to gm-csf

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided.
Morphotek, Inc.

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.

Autoimmune topics:
  • Autoimmune
  • Immune Disease
  • Autoimmune Disease
  • Immune Diseases
  • Autoimmune Diseases
  • Transplant
  • Immune Disorder
  • Autoimmune Disorder
  • Autoimmune Disorders
  • Infectious
  • Infectious Disease
  • Inflammatory Disease
  • Type 1 Diabetes
  • Proliferative Disorder
  • Recurrence

  • Follow us on Twitter
    twitter icon@FreshPatents


    This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.


    file did exist - 3268

    2 - 1 - 64